Search

Xencor Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

28.84 4.27

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

27.13

Max

29.23

Pagrindiniai rodikliai

By Trading Economics

Pajamos

107M

-22M

Pardavimai

47M

51M

Pelnas, tenkantis vienai akcijai

-0.29

Pelno marža

-42.422

Darbuotojai

260

EBITDA

109M

-12M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+8.96% upside

Dividendai

By Acuity

Kitas uždarbis

2026-11-03

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

281M

1.7B

Ankstesnė atidarymo kaina

24.57

Ankstesnė uždarymo kaina

28.84

Naujienos nuotaikos

By Acuity

50%

50%

150 / 340 reitingas Healthcare

Xencor Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-24 19:46; UTC

Xencor Inc's shares are higher Monday, rebounding from an earlier low amid rising oil prices and geopolitical tensions, despite no specific company news.

2026-08-21 21:41; UTC

Xencor Inc shares are higher in after-market trading, following a recent trend that shows a 44% increase over the past month.

2026-08-20 19:56; UTC

Correlated Moves

Xencor Inc shares declined during Thursday's session amid broader sector weakness, influenced by negative sentiment following Walmart's disappointing earnings report.

2026-08-19 20:03; UTC

Xencor Inc shares are higher during Wednesday's session, driven by strong market performance and high trading volume. No specific news was identified to explain the move.

2026-08-18 20:03; UTC

Xencor Inc shares are trading higher today, supported by strong upward momentum and unusually high market volume. No specific news was identified for the movement.

2026-08-17 19:26; UTC

Social Media

Xencor Inc shares are lower despite increased institutional interest, including Johnson & Johnson's $12 million acquisition of 748,062 shares.

2026-08-14 19:16; UTC

Shares of Xencor Inc. are modestly higher amid cautious broader market sentiment following a decline in U.S. retail sales for July.

2026-08-13 19:21; UTC

Xencor Inc shares are lower today, with no specific news driving the decline. High trading volume suggests increased activity amid routine fluctuations.

2026-08-12 19:56; UTC

Social Media

Xencor Inc shares are higher, supported by social media discussions valuing the company at $1.3 billion based on its ENPP3 asset potential.

2026-08-11 19:26; UTC

Xencor Inc shares are advancing, continuing a four-session trend. Investors are focused on upcoming inflation reports that may influence market sentiment.

2026-08-10 19:31; UTC

News

Xencor Inc shares are higher today, buoyed by increased institutional investments from Dimensional Fund Advisors and BVF Inc. IL.

2026-08-07 23:16; UTC

Xencor Inc shares are higher in after-market trading, supported by decreased interest rate hike expectations following a Labor Department report on non-farm payrolls.

2026-08-06 20:03; UTC

News

Xencor shares are higher as Cantor Fitzgerald raises its price target to $44, reflecting confidence in the company's pipeline and upcoming ESMO Congress presentation.

2026-08-03 19:51; UTC

Xencor Inc's shares are declining, continuing a downward trend since Friday's close, despite a broader market rally in technology and airlines.

2026-07-31 20:03; UTC

Xencor Inc shares are lower, reversing earlier gains amid rising US Treasury yields and crude oil prices, contributing to inflation concerns and interest rate expectations.

2026-07-30 19:03; UTC

News
Social Media

Xencor Inc. gains following a $105 million settlement with Alexion, boosting investor confidence and extending its operating runway through 2028.

2026-07-29 19:36; UTC

Xencor Inc. shares are lower as broader market trends decline ahead of the Federal Reserve's policy announcement, amid rising oil prices and inflation concerns.

2026-07-28 20:07; UTC

Xencor Inc is gaining amid a strong Biotechnology sector, despite earlier declines. The stock has rebounded to settle near the upper end of its one-month range.

2026-07-27 19:11; UTC

Xencor Inc shares are higher today, reflecting a positive market environment despite earlier intraday pullbacks. No specific news was identified to explain the movement.

2026-07-24 19:11; UTC

Xencor Inc shares are lower in Friday's session, reflecting broader market trends. No specific news was identified to explain the price movement.

2026-07-22 20:06; UTC

Xencor Inc shares are lower today, retracing from an earlier peak. Broader market sentiment is affected by uncertainty ahead of the Federal Reserve meeting.

2026-07-21 19:02; UTC

Social Media

Xencor Inc. shares reached a new 52-week high, driven by developments in RCC related to ENPP3 and immuno-oncology efforts involving TL1A.

2026-07-20 19:41; UTC

Social Media

Xencor Inc's shares are higher as clinical results are accepted for presentation at the ESMO conference, with a Phase 3 trial planned for 2027.

Akcijų palyginimas

Kainos pokytis

Xencor Inc Prognozė

Kainos tikslas

By TipRanks

8.96% į viršų

12 mėnesių prognozė

Vidutinis 30.29 USD  8.96%

Aukščiausias 44 USD

Žemiausias 20 USD

Remiantis 10 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Xencor Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

10 ratings

9

Pirkti

1

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

150 / 340 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Neutral

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Vidutinis

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Xencor Inc

Xencor, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The Company uses its engineering capabilities to enable its understanding of protein structure and interactions to design XmAb technologies and develop candidates with properties. Its antibody design is focused on the segment of antibodies that interact with target antigens. It is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Vibecotamab, Tidutamab, XmAb841, XmAb104, XmAb306, XmAb104, XmAb564 and XmAb698.
help-icon Live chat